Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Sofia Terlizzi, Giovanni Reddiconto, Paola Stefanoni, Jacopo Micozzi, Silvia Mangiacavalli, Elena Zamagni, Massimo Offidani, Anna Furlan, Gabriele Buda, Sr., Flavia Lotti, Carmine Liberatore, Antonio Lazzaro, Roberta Della Pepa, Giuseppe Bertuglia, Emiliano Barbieri, Concetta Conticello, Claudio De Magistris, Lorenzo De Paoli, Velia Bongarzoni, Anna Maria Cafro, Anna Mele, Pietro Benvenuti, Claudio Cerchione, Cirino Botta, Elisabetta Antonioli, Nicola Sgherza, Sara Aquino, Giuseppe Mele, Gregorio Barila, Salvatore Palmieri, Ombretta Annibali, Rosario Bianco, Massimiliano Arangio Febbo, Gloria Margiotta Casaluci, Angela Rago, Raffaele Fontana, Francesca Farina, Ernesto Vigna, Antonella Bruzzese, Catello Califano, Angela Amendola, Daniela Roccotelli, Alessandra Lombardo, Annalisa Citro, Giuseppina Uccello, Renato Zambello, Alessandro Maggi, Santo Neri, Michele Monachesi, Alessandro Gozzetti, Vittorio Montefusco, Marino Brunori, Nicola Di Renzo, Marta Coscia, Valerio De Stefano, Antonino Neri, Francesco Di Raimondo, Fortunato Morabito, Pellegrino Musto, Massimo Gentile

Blood (2024) 144 (Supplement 1): 4699.

https://doi.org/10.1182/blood-2024-206008

Published: 2024

Journal Articles

First-Line Daratumumab-Based Regimens in Multiple Myeloma Patients Aged 65-70 Years: A Pilot Real-World Study on Efficacy and Safety

Salvatore Palmieri, Roberta Della Pepa, Stefano Rocco, Raffaella Reina, Giuseppe Gaeta, Novella Pugliese, Aldo Leone, Fabio Trastulli, Angela Gravetti, Maria Celentano, Mariangela Pedata, Francesco Grimaldi, Fabrizio Pane, Mario Annunziata

Blood (2024) 144 (Supplement 1): 7073.

https://doi.org/10.1182/blood-2024-210292

Published: 2024

Journal Articles

Efficacy and Safety of Daratumumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Treated in an Italian Real-Life Multi-Center Retrospecive Study

Rosario Bianco, Roberta Della Pepa, Aldo Leone, Raffaele Fontana, Stefano Rocco, Angela Amendola, Salvatore Palmieri, Daniela Esposito, Daniela Roccotelli, Giuseppe Delle Cave, Maria Rosaria Spatuzzi, Roberta Spisso, Claudio Cerchione, Marialucia Barone, Cirino Botta, Daniele Derudas, Carmine Selleri, Ferdinando Frigeri

Blood (2024) 144 (Supplement 1): 7876.

https://doi.org/10.1182/blood-2024-210058

Published: 2024

Journal Articles

Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in NOVEL Agents' Era

Claudio Cerchione, MD PhD, Lucio Catalano, Davide Nappi, Stefano Rocco, Salvatore Palmieri, Anna Emanuele Pareto, Gerardo Musuraca, MD, Alessandro Lucchesi, MD, Fabrizio Pane, Felicetto Ferrara, MD, Giovanni Martinelli, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-143207

Published: 2020

Journal Articles

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial

Blood (2020) 136 (Supplement 1): 35–37.

https://doi.org/10.1182/blood-2020-136907

Published: 2020

Journal Articles

Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients

Blood (2019) 134 (Supplement_1): 605.

https://doi.org/10.1182/blood-2019-125588

Published: 2019

Journal Articles

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Alessandra Pompa, Concetta Conticello, MD, Diana Giannarelli, PhD, Loredana Pettine, MD, Laura Paris, MD, Lucia Tognazzi, Magda Marcatti, MD, Elisabetta Antonioli, MD, Francesca Fioritoni, MD, Angela Bonalumi, MD, Silvia Mangiacavalli, Paola Bertazzoni, Iolanda Donatella Vincelli, MD, Daniele Derudas, MD, Agostina Siniscalchi, Sara Pezzatti, MD, Renato Zambello, Annalisa Citro, MD, Angelo Belotti, Alessandra Lombardo, MD, Federico Vozella, MD, Adelina Sementa, MD, Ugo Consoli, MD, Alfredo Molteni, MD, Niccolò Frungillo, MD, Massimo Gentile, MD, Gabriele Buda, MD PhD, Sara Aquino, Salvatore Palmieri, Velia Bongarzoni, MD, Alessandro Inzoli, MD, Valeria Ferla, MD, Francesca Gaia Rossi, MD, Valerio Leotta, MD, Alessandra Romano, MD PhD, Federica Elia, MD, Vittorio Del Fabro, MD, Guido Montanaro, MD, Francesca Cavallaro, MD, Monica Galli, Luca Baldini, MD PhD

Blood (2019) 134 (Supplement_1): 5555.

https://doi.org/10.1182/blood-2019-125098

Published: 2019

Journal Articles

Bendamustine-Bortezomib-Desametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma : A REAL-Life Experience

Claudio Cerchione, Lucio Catalano, MD, Anna Emanuele Pareto, Santina Basile, Luana Marano, Ilaria Peluso, Luigia Simeone, MD, Orsola Vitagliano, Davide Nappi, Salvatore Palmieri, Stefano Rocco, Felicetto Ferrara, Fabrizio Pane, MD

Blood (2016) 128 (22): 5713.

https://doi.org/10.1182/blood.V128.22.5713.5713

Published: 2016

Journal Articles

FCR for Advanced Chronic Lymphocytic Leukemia: Real Life Results from a Series of 50 Patients Treated at a Single Institution

Angela Gravetti, Giuseppe Monaco, Carolina Copia, Salvatore Palmieri, Fioravante Ronconi, Stefano Rocco, Felicetto Ferrara

Blood (2015) 126 (23): 5300.

https://doi.org/10.1182/blood.V126.23.5300.5300

Published: 2015

Journal Articles

Bendamustine-Bortezomib-Desametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma : A REAL-Life Experience

Claudio Cerchione, Lucio Catalano, Anna Emanuele Pareto, Santina Basile, Luana Marano, Ilaria Peluso, Luigia Simeone, Orsola Vitagliano, Salvatore Palmieri, Stefano Rocco, Felicetto Ferrara, Fabrizio Pane, MD

Blood (2015) 126 (23): 5391.

https://doi.org/10.1182/blood.V126.23.5391.5391

Published: 2015

Journal Articles

VTD (Bortezomib Plus Thalidomide Plus Dexamethasone) Followed By Autologous Stem Cell Transplantation As First Line Treatment for Multiple Myeloma: Real Life Results from a Single Institution

Salvatore Palmieri, Angela Gravetti, Stefano Rocco, Antonella Carbone, Carolina Copia, Giuseppe Monaco, Cira Riccardi, Fioravante Ronconi, Felicetto Ferrara

Blood (2015) 126 (23): 5380.

https://doi.org/10.1182/blood.V126.23.5380.5380

Published: 2015

Journal Articles

The Poor Outcome of Multiple Myeloma (MM) Patients Carrying At Diagnosis Deleted TP53 and or Amplified MDM4 Might Be Related to the Deregulation of Genes Involved in Cell Cycle Control and DNA Damage Repair

Blood (2012) 120 (21): 1810.

https://doi.org/10.1182/blood.V120.21.1810.1810

Published: 2012

Journal Articles

Bortezomib, Melphalan, Prednisone and Thalidomide Followed by Maintenance with Bortezomib and Thalidomide (VMPT-VT) for Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of Prognostic Factors

Blood (2010) 116 (21): 620.

https://doi.org/10.1182/blood.V116.21.620.620

Published: 2010

Journal Articles

Effect of Complete Remission Achievement on Survival In Acute Myeloid Leukemia of the Elderly.

Felicetto Ferrara, MD, Cira Riccardi, Salvatore Palmieri, Tiziana Izzo, Antonella Carbone

Blood (2010) 116 (21): 1048.

https://doi.org/10.1182/blood.V116.21.1048.1048

Published: 2010

Journal Articles

Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile.

Blood (2009) 114 (22): 2811.

https://doi.org/10.1182/blood.V114.22.2811.2811

Published: 2009

Journal Articles

5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program

Blood (2008) 112 (11): 2680.

https://doi.org/10.1182/blood.V112.11.2680.2680

Published: 2008

Journal Articles

Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.

Blood (2008) 112 (11): 1662.

https://doi.org/10.1182/blood.V112.11.1662.1662

Published: 2008

Journal Articles

Bortezomib (VEL) Based Regimens in Multiple Myeloma (MM) Patients with Renal Impairment (RI): A Preliminary Retrospective Italian Multicenter Study

Blood (2008) 112 (11): 3681.

https://doi.org/10.1182/blood.V112.11.3681.3681

Published: 2008

Journal Articles

Long-Term Outcome of Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemias Arising in Patients Treated for Lymphoma or Solid Tumors.

Raffaella Milani, Salvatore Palmieri, Manuela Zanni, Filiberto Pollio, Anna Dodero, Francesco Spina, Adele Testi, Corrado Tarella, Massimo Bernardi, Andrea Gallamini, Giuseppe Bandini, Fabio Benedetti, Felicetto Ferrara, Paolo Corradini

Blood (2007) 110 (11): 2464.

https://doi.org/10.1182/blood.V110.11.2464.2464

Published: 2007

NARROW

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

First-Line Daratumumab-Based Regimens in Multiple Myeloma Patients Aged 65-70 Years: A Pilot Real-World Study on Efficacy and Safety

Efficacy and Safety of Daratumumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Treated in an Italian Real-Life Multi-Center Retrospecive Study

Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in NOVEL Agents' Era

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial

Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Bendamustine-Bortezomib-Desametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma : A REAL-Life Experience

FCR for Advanced Chronic Lymphocytic Leukemia: Real Life Results from a Series of 50 Patients Treated at a Single Institution

Bendamustine-Bortezomib-Desametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma : A REAL-Life Experience

VTD (Bortezomib Plus Thalidomide Plus Dexamethasone) Followed By Autologous Stem Cell Transplantation As First Line Treatment for Multiple Myeloma: Real Life Results from a Single Institution

The Poor Outcome of Multiple Myeloma (MM) Patients Carrying At Diagnosis Deleted TP53 and or Amplified MDM4 Might Be Related to the Deregulation of Genes Involved in Cell Cycle Control and DNA Damage Repair

Bortezomib, Melphalan, Prednisone and Thalidomide Followed by Maintenance with Bortezomib and Thalidomide (VMPT-VT) for Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of Prognostic Factors

Effect of Complete Remission Achievement on Survival In Acute Myeloid Leukemia of the Elderly.

Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile.

5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program

Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.

Bortezomib (VEL) Based Regimens in Multiple Myeloma (MM) Patients with Renal Impairment (RI): A Preliminary Retrospective Italian Multicenter Study

Low Dose Rituximab in Adult Patients with Idiopathic Thrombocytopenic Purpura.

Long-Term Outcome of Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemias Arising in Patients Treated for Lymphoma or Solid Tumors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only